Clinical Trial: New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases

Brief Summary: Chagas disease is endemic to Latin America, and is of emerging importance in non-endemic countries because migration of people infected with T. cruzi. Current methods for diagnosis of T. cruzi infection are not ideal. Existing drugs for treatment are very limited, produce severe side-effects, and their effectiveness cannot be properly evaluated. Reliable biomarkers for prognosis, early diagnosis and effectiveness of treatment will be investigated.

Detailed Summary:
Sponsor: Barcelona Centre for International Health Research

Current Primary Outcome: Biomarkers for prognosis, early diagnosis and effectiveness of treatment. [ Time Frame: 2 years ]

  • Conventional polymerase chain reaction of T. cruzi in blood
  • Measurement of Brain natriuretic factor
  • Measurement of Prothrombotic factors
  • Measurement of antibodies against specific proteins of the trypomastigote of T. cruzi
  • Investigation of the phylogenetics of the parasite and the role of the lineages of T.cruzi in the clinical presentation and disease's progression


Original Primary Outcome: Same as current

Current Secondary Outcome: Cardiac function after antiparasitic treatment [ Time Frame: 2 years ]

- Correlation between biomarkers and alterations of the left ventricle diastolic function and segmentary contractility after antiparasitic treatment


Original Secondary Outcome: Same as current

Information By: Barcelona Centre for International Health Research

Dates:
Date Received: December 19, 2012
Date Started: December 2012
Date Completion:
Last Updated: August 19, 2016
Last Verified: August 2016